Thompson Rahsaan's Form 4 filing
Zevra Therapeutics, Inc. (ZVRA) · filed Aug 17, 2026
- Accession no.
- 0001434647-26-000073
- Filed
- Aug 17, 2026, 4:32 PM ET
- Trade date
- Aug 14, 2026
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $474.8K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Thompson RahsaanCIK 0001788524 | Officer (Chief Legal & Compliance) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | Common Stock | SSaleDisposed | −42,666 | $11.13F2 | −$474,774.45 | 37,569 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $10.86 to $11.36. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.